Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-30
2009-12-29
Silverman, Eric E. (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07638516
ABSTRACT:
The medicament for therapeutic and/or prophylactic treatment of the present invention has a suppressing action on the retinal degeneration induced by transient retinal ischemia, which is verified by the results for suppressing effect on retinal degeneration in transient retinal ischemia eye. Therefore, the medicament of the present invention has a therapeutic and/or prophylactic effectiveness on diseases in optic nerve and the like.
REFERENCES:
patent: 4857542 (1989-08-01), Nishi et al.
patent: 5837723 (1998-11-01), Watanabe
patent: 35 33 662 (1986-03-01), None
patent: 609822 (1994-08-01), None
patent: 633025 (1995-01-01), None
patent: 2608045 (1988-06-01), None
patent: 03 215425 (1991-09-01), None
patent: 9-278652 (1997-10-01), None
patent: 10 218771 (1998-08-01), None
patent: 93/00088 (1993-01-01), None
patent: 98/32863 (1998-07-01), None
Opere et al., Regulation of Uveal Sympathetic Neurotransmission by Peroxides. Investigative Ophthalmology & visual Science, Apr. 1997.
Abstract of: Cheung et al., Z. H. “Mixture of American ginseng extract, Ginkgo biloba extract and St. John's wort extract enhances the survival of axotomized retinal ganglion cells.” 30th Annual Meeting of the Society of Neuroscience; New Orleans, LA, USA; Nov. 4-9, 2000. PUB Society for Neuroscience Abstracts, vol. 26, nr. 1-2, abstract nr. 123.16.
Babovic et al., S. “Role of reactive oxygen species in optic nerve compression injury: A preliminary study.” Annals of Plastic Surgery. United States. ISSN 0148-7043. vol. 40, nr. 2, pp. 156-159 (1998).
Bemired et al., S. “Effect of radical scavengers on ocular hemodynamics and on the visual field in primary open angle glaucoma.” Annual Meeting of the Association for Research in Vision and Ophthalmology; Fort Lauderdale, Florida, USA; Apr. 21-26, 1996. Investigative Ophthalmology and Visual Science, vol. 37, nr. 3, p. S270, CONF. (1996).
Eschweiler et al., G. W. “Free-radical scavengers support retinal ganglion cell survival after traumatic optic nerve lesions.” 26th Annual Meeting of the Society for Neuroscience; Washington, D.C., USA; Nov. 16-21, 1996. Society for Neuroscience Abstracts, vol. 22, nr. 1-3, p. 317, CONF. (1996).
Roth et al., Current Eye Research, vol. 16, pp. 875-885, 1997.
Inoue Eri
Mano Tomiya
Sogou Shunji
Mei Co., Ltd.
Silverman Eric E.
Wenderoth Lind & Ponack LLP
LandOfFree
Agent for therapeutic treatment of optic nerve diseases and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agent for therapeutic treatment of optic nerve diseases and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for therapeutic treatment of optic nerve diseases and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4093794